title: Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia.
abstract: BACKGROUND
  For T-malignancies in children a poor prognosis is reported. In these malignancies a combination of lymphoma and leukemia is commonly seen at presentation and most patients are treated according to protocols for acute lymphoblastic leukemia (ALL). These protocols are often designed for the majority of ALL cases, i.e., progenitor-B-ALL. In pediatric lymphoblastic non-Hodgkin's lymphoma without bone marrow infiltration various protocols have been used. The most frequently reported regimens show variable survival rates between 40 and 75%.
  
  
  METHODS
  From 1989 we have treated 32 consecutive patients with T-cell malignancies, irrespective of localization, with a protocol consisting of a 4-agent induction treatment followed by high doses of methotrexate, and cytosine-arabinoside and intensified bleomycin, adriamycin, cyclophosphamide, vin cristin, prednisone (BACOP) courses. Treatment duration for each patient was 1 year. Twenty-one of the 32 patients had stage IV disease. Follow-up ranged from 1.6 to 7.6 years (median 4.2 years).
  
  
  RESULTS
  Overall event-free survival (EFS) was 72%, while in those with stage IV disease it was 67%. No therapy-related deaths occurred. Neither stage, initial leukocyte value, mediastinal involvement, bone marrow involvement, nor the presence of CD1, CD3, CD4, CD8, or CD10 epitopes was prognostically significant. Evaluation of toxicity revealed a minimal decrease of carbon monoxide diffusion and cardiac shortening fraction.
  
  
  CONCLUSIONS
  A relatively short but intensive chemotherapy can be used in T-cell malignancies. The EFS is satisfying, but larger studies are needed.
authors.affiliation: Department of Pediatric Oncology, Emma Kinderziekenhuis AMC, Academic Medical Center, University of Amsterdam, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: van den Berg
authors.forename: J
authors.initials: J
authors.lastname: Zsiros
authors.forename: A
authors.initials: A
authors.lastname: Veneberg
authors.forename: N J
authors.initials: NJ
authors.lastname: Schutten
authors.forename: W
authors.initials: W
authors.lastname: Kroes
authors.forename: R M
authors.initials: RM
authors.lastname: Slater
authors.forename: H
authors.initials: H
authors.lastname: Behrendt
mesh_terms: D000293:Adolescent; D015703:Antigens, CD / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD